The natriuretic peptides (NP) appear to be functional by midgestation, respond to volume stimuli, and regulate blood pressure and salt and water balance in the developing embryo. In addition, the NP may help regulate the blood supply to the fetus, acting as vasodilators in the placental vasculature. Peaks of ANP and BNP expression during gestation coincide with significant events in cardiac organogenesis, suggesting a role for NP in the formation of the heart. Levels of atrial natriuretic peptide (ANP) are higher in the fetal circulation than in adults, and fetal ventricles express higher levels of ANP and B-type natriuretic peptide (BNP) than adult ventricles. In this comprehensive review we have discussed the role NP during development of the fetal heart and circulation and in various cardiovascular diseases of neonatal and pediatric age group.
INTRODUCTION
Natriuretic peptides (NP) are a group of polypeptide hormones that are structurally similar and share the same amino acid ring ( Fig. 1) but are genetically distinct. They are natural antagonists to renin angiotensin aldosterone system and play a very important role in the regulation of extracellular fluid and electrolyte balance as well as blood pressure and affect the internal milieu by their actions of natriuresis, diuresis, vasodilation, inhibition of sympathetic system, and complex interaction with cytokines and vasopressin (Fig. 2) . We have discussed the essential biochemistry, physiological properties of NP and their functional implications in cardiovascular medicine in general in our previous review [1] . This review discusses the developmental ontogeny of NP with respect to cardiac embryogenesis, normal levels of NP in neonates, infants and children and their involvement in different cardiovascular diseases including pulmonary hypertension, congenital heart disease, cardiomyopathy, Kawasaki disease (KD), heart failure, cardiac transplantation and during perioperative period of cardiac surgery in infants and children.
DEVELOPMENTAL ONTOGENY OF NP
Temporal and morphogenetic patterns of NP during embryogenesis have been extensively studied in mouse models and human embryos and have been postulated to play an important role in the cardiac development [2] . Using in situ hybridization techniques in mouse embryos, very intense expression of ANP and BNP were visible in developing heart from 8.5 days of gestation, attaining a peak level at 12.5 days with smaller peaks at 14.5 days and 16.5 days and then start declining at birth [3] . This pattern correlates well with the different stages of cardiac development including regular embryonic heart beating, septation and changing axis of the heart. The developing human fetal atria and ventricles possess substantial capacity to express ANP gene and contribute significantly to the circulating pool of plasma ANP. ANP messenger ribonucleic acid (mRNA) levels in ventricles were on an average about 20% of those in atria. ANP immunoreactivity in ventricle was less than 5% of that in the right atrium, suggesting important differences in the way these tissues synthesize and store the ANP peptide. Diffuse homogenous distribution of ANP gene expression is seen in atrial myocardium. A similar low level expression is seen in ventricular myocardium along with scattered foci of increased expression in ventricular subendocardium [4] . High levels of ANP gene expression during cardiac embryogenesis has been explained by two ways [5] . Firstly, the predominant segregation of ANP expressing cells in developing atria and ventricle during torsion and differential growth of cardiac tubes and nonexpressing cells in bulbus cordis. Secondly, ANP mRNA transcription can be initiated in all cardiac cells in response to appropriate stimuli. Differential oxygenation and blood flow may account for regional regulation of ANP expression with atria and left ventricle (LV) receiving similar and greater stimuli for gene activation compared to right ventricle (RV). The fetal secretion of cardiac NP occurs in response to similar pathophysiologic stimuli as in adult animal models including volume loading, hypoxia, hyperosmolality and vasoconstriction [6] [7] [8] [9] . These appear to suggest that, NP are functional by midgestation and play an important role in the blood pressure regulation and salt and water balance in developing embryo. All NP can suppress cardiac fibroblast growth and play a key role in cardiac organogenesis [10] . Knock out mice with either ANP or BNP gene disruption show no changes in size or structure of neonatal hearts possibly due to compensation of one by the other, but disruption of both induces cardiac hypertrophy in fetal mouse models [11, 12] . ANP immunoreactivity is concentrated in the atrial myocardium and ventricular conduction system but is also detected in the early fetal ventricular myocardium. The ventricular conduction system is an extra-atrial site for the synthesis of ANP. In the failing heart this synthesis may be further supplemented by expression of the gene in the ventricular myocardium. It is possible that ventricular production of the peptide contributes to the raised circulating concentrations of ANP [13] .
Current knowledge limits the understanding of importance of C-type natriuretic peptide (CNP) in fetal cardiac development. CNP plasma concentration has been measured in normal human fetuses and in the conditions of rhesus isoimmunization and structural malformations, but the source of CNP generation is not yet known. CNP expression has not yet been shown to be detectable in the heart of human embryos though low cardiac CNP mRNA concentration is seen in mouse embryos [14] . However, human heart in pathophysiological conditions of heart failure has been recently identified as a site of CNP expression [15] . Also, fetal CNP plasma levels remain stable after volume load during intravascular transfusion in contrast to ANP and BNP levels [16] .
NORMAL LEVELS OF NP IN NEONATES, INFANTS AND CHILDREN
NP especially BNP and NT-pro BNP play a key role in the circulatory changes occurring during the transition from fetal to neonatal period. ANP, BNP and NT-pro BNP plasma concentrations in healthy newborns are very high in the initial few days of life (BNP levels between 200 and 500 pg/ml) and decrease rapidly during the first week of life (BNP level < 50 pg/ml). This is probably related to the neonatal circulatory transition including increased pulmonary blood flow, decreasing pulmonary vascular resistance and gradual maturation of renal function. There is no significant difference in plasma amino terminal pro-ANP and NT-BNP concentrations between umbilical venous cord blood and peripheral venous blood on the day of delivery [17] . The plasma BNP concentration on the day of delivery (56.7 +/-49.6 fmol/ml) is 25 to 30 times higher than the adult level and 21 times higher than that in the umbilical vein (2.7 +/-1.4 fmol/ml) [18] . It declines through early infancy and is almost constant and at the adult level after 3 months of age. The plasma ANP concentration on the day of birth is not significantly different from that in the umbilical vein [18] . The ratio of BNP to ANP is also the highest at 0 days of age (1.39 +/-0.72), thus suggesting a physiological role for BNP distinct from that of ANP in the perinatal circulatory changes from fetus to neonate. Several studies have shown a dramatic increase in levels of NT-proBNP in the period immediately after birth [17, 19, 20] . Also, the most significant changes in the levels of NT-proBNP occur in the first 48 hours of life and diminish toward normal values within 1 week post delivery. The increase and decrease of NP values correlate with the expected 10%-15% perinatal weight loss in the first week of life. The level of BNP is < 32.7 pg/ml in healthy infants, children, and adolescents after 2 weeks of age [21] . Similar to term infants, BNP levels in pre-term infants are related to the chronological age and decline during the first month of life [22] .
The plasma NT-proBNP levels reported in children and adolescents range between 0 and 109 fmol/ml (mean, 7.4) Fig. (1) . The Natriuretic Peptide Family. [23] . There is no difference in plasma BNP measured in boys and girls younger than 10 years (8.5 pg/ml). There seems to be a sex-related difference in the second decade of life with higher BNP levels in girls related to pubertal stage [22] . The plasma concentration of BNP in girls aged 10 years or older is significantly higher than in boys of the same age group (12.1 vs. 5.1 pg/ml) (p < 0.001) [22] .
PERSISTENT PULMONARY HYPERTENSION (PPHN) IN NEWBORN
The diagnosis of PPHN can often be difficult to make, especially in a clinical setting in which pediatric echocardiography is not readily available. BNP does not cross the placenta and maternal levels of elevated BNP do not affect its level in the fetus or newborn. In a prospective study designed to evaluate the BNP levels in neonates with respiratory distress with and without PPHN, initial BNP levels are elevated in the PPHN group relative to both the respiratory distress without PPHN and newborns breathing in room air without any respiratory distress. [24] An initial BNP level > 550 pg/ml is predictive of PPHN with sensitivity of 83% and specificity of 100% [23] . A rising BNP level indicates a worsening clinical condition and appears to be more important marker of disease severity than the actual level present. BNP levels correlate with echocardiographic estimates of pulmonary pressure by tricuspid regurgitation jet but not with clinical measures of disease severity. Also BNP measurements are not affected by the use of dopamine or dobutamine, urine output or ventricular function in patients with PPHN. BNP level is a sensitive biomarker that can be used as an adjunct to other clinical and laboratory information in confirming the diagnosis of PPHN, or suggesting some other cause of ventricular dysfunction.
PULMONARY HYPERTENSION, CYSTIC FIBROSIS, CONGENITAL DIAPHRAGMATIC HERNIA
Studies in adults show that BNP is increased and correlated with MRI parameters of RV remodeling and function, end diastolic and end systolic volumes, RV mass, leftward ventricular septal bowing and ejection fraction in chronic thromboembolic pulmonary hypertension patients [25] . Hemodynamically, BNP levels greater than 48.5 pmol/L identified the most severely affected patients. In patients with primary pulmonary hypertension, the BNP levels positively correlate to pulmonary vascular resistance, pulmonary artery pressure and right arterial pressure and are inversely related to cardiac index [26] . A high level of plasma BNP, and in particular, an increase in plasma BNP during followup, may have a strong, independent association with increase mortality rates in patients with primary pulmonary hypertension [27] . Elevation of left atrial pressure as a result of LV dysfunction in cases with pulmonary venous hypertension and elevation of right atrial pressure as a result of pulmonary hypertension caused by impairment of the respiratory muscles are considered to be involved in the mechanism of increased plasma ANP levels in patients with Duchenne's progressive muscular dystrophy. However no clear correlation is observed between ANP levels and wall motion abnormalities of the LV [28] .
The diagnosis of right heart failure and pulmonary hypertension in cystic fibrosis (CF) patients with advanced pulmonary disease is sometimes difficult on clinical grounds alone. Elevated NT-BNP level in CF patients is found to be a predictor of pulmonary hypertension and heart failure [29] . There occurs over expression of genes for BNP, components of rennin-angiotensinogen and endothelin-1 in RV in congenital diaphragmatic hernia [30] . However, in clinical setting, perceived utility of plasma BNP is to differentiate symptoms related to pulmonary hypertension associated with congenital diaphragmatic hernia from large left-to-right flow such as a PDA, eventually supporting PDA ligation despite evidence for pulmonary hypertension.
CONGENITAL HEART DISEASE
NPs have been studied for their usefulness in various congenital heart diseases to aid diagnosis, assess prognosis and for monitoring the progression of ventricular dysfunction. An elevation of NP as a marker of volume and pressure load in children appears to be due to complex interactions involving myocyte stretch, actions on cell growth and proliferation of fibroblasts, vascular smooth muscle cells and a greater possibility for compensation of LV function in younger age. In a systematic study to investigate the diagnostic validity of plasma BNP on pediatric patients with congenital heart defects, plasma BNP concentration has been found to be increased significantly with decreasing LV function [31] . Plasma BNP is also increased significantly in patients with left-to-right shunts, aortic valve stenosis, coarctation of aorta and patients with functionally univentricular heart in comparison with healthy subjects [31] . In patients with left-to-right shunt lesions, plasma BNP positively correlate to shunt volume, systolic RV pressure, mean pulmonary artery pressure and increasing pulmonary vascular resistance [31, 32] . Plasma BNP 20 pg/ml and ANP of 50 pg/ml can identify children with mean pulmonary artery pressure of 20 mmHg with a sensitivity of 82% and 97%, respectively, and a specificity of 89% and 84%, respectively [32] . No significant elevation of BNP is found in patients with pulmonary valve stenosis, tetralogy of Fallot, in patients missing a pulmonary ventricle with isolated cavopulmonary failure [31] . But, BNP levels are increased in children with RV volume overload such as atrial septal defect [33] . However, there is a small study showing paradoxical relationship of BNP and pulmonary hypertension in patients with ventricular septal defect and Eissenmenger syndrome [34] .
A significant positive correlation is seen between the plasma concentration of BNP and the size of the patent ductus arteriosus (PDA) and degree of shunting. [35] BNP >300 pg/ml predicts presence of a hemodynamically significant PDA, whereas BNP <105 pg/ml predicts the absence of a hemodynamically significant PDA. The accuracy of BNP for predicting the presence and magnitude of PDA has been cited in literature, [36, 37] however the clinical applicability of the bedside BNP in the neonatal intensive care unit remains to be determined [35, 38, 39] . Bedside measurement of BNP correlates with magnitude of PDA in premature newborns also, particularly beyond day 2 and may be used in conjunction with clinical judgment and echocardiography in guiding management strategies in the care of premature newborns. Serial BNP measurement is more valuable in determining the clinical course of PDA in preterm infants.
Plasma BNP and ANP significantly correlate with the patients' growth failure as expressed by bodyweight; the higher the plasma BNP and ANP, the lower the bodyweight [35] . The impact of ventricular morphology in different congenital heart diseases per se on NP levels has also been reported [40] . Plasma concentrations of BNP and ANP are higher in children with congenital heart disease with LV volume overload compared with RV volume overload or pressure overload. The BNP and ANP correlated with the LV inner diameter in diastole Z score and left atrium to aortic ratio. BNP levels also reflect the severity of the impairment of systemic RV function in Senning patients in whom a complex RV geometry is present causing the assessment of RV function more difficult, BNP measurements as a longitudinal test in this patient group is also useful to monitor ventricular function [41] .
In children with congenital heart defects plasma BNP increase immediately after cardiac surgery despite hemodynamic unloading. The correlation to cardiopulmonary bypass time and serum lactate concentration and the similarity between the pattern of BNP release after surgery and after myocardial ischemia may be explained by a cytoprotective role of BNP after cardiac surgery [42] . Further studies are required to determine the value of BNP for the follow-up and setting up of prognostic values in children with congenital heart disease.
CARDIOMYOPATHIES
The measurement of plasma BNP has emerged as a useful biomarker of heart failure in patients with cardiomyopathy. BNP levels correlate with non-invasive parameters of disease severity in children with hypertrophic cardiomyopathy, including measures of elevated LV filling pressures [43] . BNP is also a useful tool in the assessment of disease severity in dilated cardiomyopathy. BNP levels are elevated in children with LV dysfunction compared with healthy controls (median, 78 pg/mL versus median, 7 pg/mL; P < 0.0001). BNP concentrations are elevated in children with chronic LV systolic dysfunction and predict the 90-day composite end point of death, hospitalization, or listing for cardiac transplantation [44] . In another study, the median levels of ANP and BNP in children with clinically symptomatic heart failure are 412 ng/L (148 -553) and 638.5 ng/L (263 -1300) respectively, irrespective of whether the heart failure is due to dilated cardiomyopathy or associated with volume overload such as ventricular septal defect with normal systolic function [45] .
BNP is a proteomic marker for monitoring cardiac function in children receiving chemotherapy such as anthracycline [46, 47] . The plasma BNP levels are helpful in differentiating between idiopathic constrictive pericarditis and restrictive cardiomyoapthy. BNP level would be low in idiopathic constrictive pericarditis, but high in restrictive cardiomyopathy [48] .
KAWASAKI DISEASE
KD is a small and medium vessel generalized vasculitis with prominent cardiovascular manifestations involving pericardium, myocardium, endocardium and coronary vessels. Plasma BNP is a useful biochemical marker for the myocarditis of KD. Abnormal myocardial mechanics may contribute to the increased plasma BNP level and enhanced oxidative stress may contribute to cardiac dysfunction in KD. The plasma BNP concentration in patients with KD in the acute phase is significantly higher (mean BNP level 55.0+/-39.5 pg/ml) than in patients with viral infection (mean BNP level 6.8+/-7.3 pg/ml) (P<0.0001) [49] . When the plasma BNP level is > 16.8 pg/ml, KD is suggested with a sensitivity of 96.6% and specificity of 86.2% [49] . Plasma levels of BNP may be helpful in the diagnosis of atypical cases and for early diagnosis of KD. However possibility of KD cannot be excluded in patients with normal plasma BNP levels. The BNP level in patients with KD and pericardial effusion was significantly higher than that of patients without pericardial effusion [49] .
In another study, plasma BNP level is significantly higher (65+/-9 pg/ml) in children with acute KD than in controls (13+/-2 pg/ml) [50] . Patients with the BNP titer greater than 50 pg/ml show abnormal electrocardiograms more frequently and therefore more likely to have myocarditis than those in whom the values are less than 50 pg/ml [50] . Cellular infiltration and myocardial edema is frequently found in the acute phase on postmortem examination of patients dying of KD. Because it is reported that myocardial biopsies performed up to 11 years after the onset of disease showed varying degrees of cellular infiltrates, fibrosis and abnormal myocytic structure, these authors propose that patients who have high levels have BNP during the acute phase, even without coronary involvement should be followed long term to ensure that they do not develop delayed cardiomyopathy, just as patients with coronary involvement need to be followed for coronary artery disease [51] .
In another prospective study of 25 patients with acute phase KD with preserved LV systolic function, BNP level has been found to be elevated (mean 54.0±102.8 pg/ml) [52] . The impaired diastolic function is postulated to be the cause of increased BNP level. However, no significant correlation between BNP level and LV end diastolic volume index is noted [52] .
RESPIRATORY DISTRESS: HEART FAILURE VER-SUS LUNG DISEASE
Studies have shown the utility of BNP in differentiating heart failure from lung disease in pediatric patients with respiratory distress [53, 54] . In the study to determine whether plasma levels of NT-BNP can differentiate between heart failure and lung disease among infants with acute respiratory distress, the highest NT-BNP level among the lung patients was 1341 pg/ml and the lowest level among the cardiac patients was 5375 pg/ml [53] . The calculated cutoff NT-BNP value differentiating cardiac patients from control and lung patients was 2840 pg/ml [53] . Plasma NT-BNP levels are also found to be a reliable indicator of clinical improvement as they correlate with a significant increase in room air oxygen saturation and a significant decrease in respiratory rate after treatment for heart failure. A BNP level > 40 pg/ml is 84% accurate in differentiating heart failure from pulmonary disease [53] . A very high level of NT-BNP as discussed above in the review, although specific for decompensated heart failure, does not exclude the presence of co-morbidities and proper assessment of these patients during an acute exacerbation requires comparison of their actual NT-BNP levels with the baseline values.
ROLE OF NP IN MANAGEMENT OF HEART FAIL-URE
The synthesis and release of the NP rises incrementally in concert with the other neurohormonal responses with increasing degrees of cardiac dysfunction. Plasma ANP and BNP levels correlate positively with cardiac filling pressure (right atrial and pulmonary capillary wedge pressure) and are inversely related to LV ejection fraction [55] [56] [57] [58] . The high levels of plasma ANP are attributed to increased right-sided heart production rather than to decrease clearance. Although volume-induced atrial stretch is the main source for the elevated circulating ANP levels in heart failure, enhanced synthesis and release of the hormone by the ventricular tissue in response to angiotensin II and endothelin also contribute to this phenomenon [59, 60] . In a study on plasma levels of NT-proBNP in infants and children with and without heart diseases, the median value in infants and children 4 months or older with heart disease was 1321 pg/ml, significantly greater than that of normal children [60] . The mean BNP level in children with heart failure is 100 pg/ml. Patients with acute LV dysfunction due to acute myocarditis and acute cardiomyopathy have the highest BNP Levels (median BNP 58,000 pg/ml, range 29,000 pg/ml -288,000 pg/ml). Patients with high pressure left-to-right shunt, at the ventricular or great artery levels, had higher BNP than patients with low pressure left-to-right shunt, at the atrial level [60] . In another study, the mean (± standard error) NT-proBNP level was 77,351 ± 22,879 pg/ml (median, 63,260 pg/ml) in children with acute LV dysfunction [61] . Follow-up measurements of NT-proBNP in patients with acute LV dysfunction indicate that the highest levels are measured during the first 24 hours of acute illness. Also, it has been found that higher levels of NT-proBNP (> 20,000 pg/ml) are more likely to be due to acute exacerbation in patients with known heart failure. Because systolic cardiac function did not differ between the groups of acute versus chronic LV dysfunction, the authors of the study proposed that the excessive elevation of NTproBNP levels resulted not only from a surge in NT-proBNP production in reaction to the acute muscle dysfunction and increased wall tension but also from myocyte injury and death, impaired perfusion to other organs (e.g., liver or kidney), acidosis and high levels of stress hormones [61, 62] .
In a study to determine the secretion of ANP and BNP into the bloodstream and pericardial space in children with congenital heart disease and a possible pathophysiologic role of NP in heart failure as an autocrine and paracrine factor, BNP levels in pericardial fluid showed marked elevations compared with those in plasma and ANP levels in pericardial fluid were lower than those in plasma [63] . It has been well demonstrated in adults that administration of diuretics and angiotensin converting enzyme inhibitors reduce plasma concentrations of BNP in association with improvement of symptoms and cardiac function [63, 64] . In a pilot study on approximately 70 adult patients with ejection fractions < 40% and a history of recent decompensated heart failure, the therapy guided by serial measurements of plasma BNP produced superior clinical outcome to that guided by a clinical acumen alone [65] . Data in children is still to evolve in this area of therapeutic implications. Left atrial volume index (LAVI) is increasingly recognized as a relatively loadindependent marker of LV filling pressures. Studies in adults have shown LAVI in patients with suspected heart failure with preserved systolic function is a powerful independent predictor of LV diastolic dysfunction, and is the most consistent predictor of NT-proBNP level [66] . These data are yet to be validated in children.
CARDIAC TRANSPLANTATION
BNP is chronically elevated in heart transplantation and reflects diastolic dysfunction, cardiac allograft vasculopathy, and poor late outcome. BNP has also been shown to be elevated in children with cardiac transplants who have signs of rejection. In a study on 59 pediatric heart transplant patients, BNP levels are significantly lower in patients with a biopsy specimen negative for rejection than those patients with a biopsy positive (p<0.04) for rejection [67] . Higher plasma BNP levels are observed in the presence of worsening LV hypertrophy and LV function. BNP levels significantly decrease with treatment (p <0.007) [67] . Within these patients, the decrease in BNP levels reflected the trend in improvement of allograft rejection grade. Though with wide individual variability and higher BNP levels in some non-rejection patients, it has been proposed that patients with BNP levels substantially above their baseline values may raise concerns about allograft rejection and require further evaluation. Rapid bedside BNP analysis may provide a noninvasive surrogate method for the comprehensive assessment of cardiac allograft function. Hemodynamic data in patients with heart transplantation such as elevated pulmonary capillary wedge pressure, lower cardiac index, and symptoms of dyspnea and fatigue have been shown to be independent predictors of BNP levels [68] . In clinically quiescent heart transplant recipients, an elevated BNP concentration significantly correlate with peripheral gene expression in the domains of gelsolin (actin cytoskeleton), matrix metallopeptidases (collagen degradation), platelet function, and immune activity (human leukocyte antigen system, heat shock protein, mast cell, and B-cell lineage). These molecular patterns reflect ongoing active cardiac structural remodeling, vascular injury, inflammation, and alloimmune processes and enhance the important additional role of BNP as an evaluation tool [69] . Studies have shown that increasing BNP concentrations precede cardiac allograft rejection and can be independently predictive of survival in patients long after cardiac transplantation [70] . NT-proBNP is found to be the an independent predictor of mortality one week after transplantation with possible explanations being an elevated NT-proBNP concentration indicative of LV or RV dysfunction secondary to myocardial insult, renal dysfunction, or multiorgan failure [71] . The negative predictive value of NT-proBNP levels <800 pg/ml to predict death was 97% indicative of a midterm good survival in heart transplant recipients [72] .
PERIOPERATIVE PERIOD AFTER CARDIAC SUR-GERY
NPs including ANP, BNP and NT-proBNP have been established as diagnostic and prognostic markers in patients with several heart diseases as discussed above in this review and have become objects of attention in additional fields of cardiology including the perioperative period after repair of congenital heart defects. BNP and NT-proBNP levels measured preoperatively and postoperatively are useful in the management of the pediatric patient after congenital heart surgery [73, 74] . In a study on the impact of cardiac surgery on plasma concentration of BNP in children with congenital heart disease, median preoperative plasma BNP level was 31 pg/ml(range 5-1300 pg/ml, mean 189 pg/ml) [76] . Plasma BNP level increase significantly in a biphasic pattern after cardiac surgery with two peaks at 1.3 and 5.1 days postbypass. All postoperative BNP plasma concentrations in the first 10 days after surgery are significantly elevated compared to preoperative data. In the second week, BNP decrease to the upper end of normal range in some patients, but is still markedly elevated in the majority of patients. At follow-up 2-27 months after surgery, plasma BNP returns to normal range in nearly half of the patients. Compared to patients with simple cardiac defects, BNP is significantly higher in patients with complex anatomy before surgery and during the postoperative follow-up. Preoperative NTproBNP levels also correlate with the complexity of surgical repair, as measured by cardiopulmonary bypass time and with postoperative measures, including fractional inhaled oxygen requirements and duration of mechanical ventilation [75] . Plasma NT-proBNP concentrations correlate with the severity of heart failure in children and adolescents after Fontan and bidirectional cavopulmonary anastomosis operation [76, 77] .
BNP has a complex role as a pleiotropic peptide beyond its natriuretic and cardiac unloading properties including tissue protecting effects and potent actions on cell growth and proliferation of fibroblasts, vascular smooth muscle cells and cardiac myocytes [78] [79] [80] . NP may have a cytoprotective role after cardiac surgery seems to be explained by the correlation of the BNP increase to cardiopulmonary bypass time and serum lactate concentration and the similarity between the pattern of BNP release after surgery and after myocardial ischemia. Plasma BNP and NT-BNP levels measured preoperatively and postoperatively are prognostic indicators in the management of the pediatric patients after surgical intervention for congenital heart repair.
THERAPEUTIC USES: RECOMBINANT BNP
Nesiritide is a human recombinant BNP approved and proven to be useful in the management of decompensated heart failure in adults. The experience of nesiritide in pediatric heart failure population is still emerging [81] [82] . In a prospective pilot study of 140 nesiritide infusions in 63 consecutive children, nesiritide infusion alone or in combination has been found to be a safe treatment for decompensated heart failure in pediatric patients [83] . Increased urine output reflects improving renal function in this setting. Improved neurohormonal markers are seen after 72 hours of therapy, and complications are uncommon. However, increased vigilance is recommended while administering nesiritide in pediatric patients.
